Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

Falling electricity prices weigh on earnings outlook for utility provider.

Adrian Atkins | 06 August 2026

This AI beneficiary may still be one of the market’s most compelling bargains.

Tyger Fitzpatrick | 06 August 2026

A closer look at the key earnings results from the first week of August reporting.

Tyger Fitzpatrick | 06 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,452.00	42.10	0.45%
CAC 40	8,736.07	66.78	0.77%
DAX 40	26,196.40	70.10	0.27%
Dow JONES (US)	54,313.22	35.90	-0.07%
FTSE 100	10,873.77	14.53	-0.13%
HKSE	25,530.28	385.54	-1.49%
NASDAQ	26,441.01	77.57	0.29%
Nikkei 225	65,683.26	617.18	-0.93%
NZX 50 Index	13,958.06	39.12	-0.28%
S&P 500	7,738.96	15.41	0.20%
S&P/ASX 200	9,271.60	41.80	0.45%
SSE Composite Index	3,900.35	21.92	0.57%